GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (NAS:EPRX) » Definitions » Stock Based Compensation

EPRX (Eupraxia Pharmaceuticals) Stock Based Compensation : $4.50 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Stock Based Compensation?

Eupraxia Pharmaceuticals's Stock Based Compensation for the three months ended in Mar. 2025 was $1.49 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was $4.50 Mil.

Eupraxia Pharmaceuticals Stock Based Compensation Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Stock Based Compensation Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial 0.18 3.31 1.43 1.41 3.22

Eupraxia Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 1.48 0.51 1.03 1.49

Eupraxia Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.50 Mil.

Eupraxia Pharmaceuticals Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (NAS:EPRX) » Definitions » Stock Based Compensation
Comparable Companies
TSX:FRX NEOE:CYBN TSX:TH TSXV:NGEN XCNQ:METX TSXV:ARCH TSX:MSCL TSX:MDNA XCNQ:GLAB TSX:ONC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
EPRX:Canada
Address
201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Website
https://www.eupraxiapharma.com
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.